Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard) ein immunonkologisches Plattformunternehmen…
mymediset, the leading provider of SAP solutions for the medical device industry, and Terso Solutions, the leading provi…
ProteinQure, the leading startup in the computational design of peptide drugs, announces a significant breakthrough in t…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
Full-year revenue increased to CHF 2.4 billion and showed 9.8% organic revenue growth Fourth-quarter revenue amounte…
. - Fresenius achieves the raised outlook for FY/23. Strong final quarter with continued good development of the Operati…
. - Fresenius erreicht angehobenen Ausblick für 2023. Starkes Schlussquartal mit anhaltend guter Entwicklung der Operati…
Platinex Inc (PTX:CSE)(9PX:FRA) had to manoeuvre carefully on their fully permitted flagship W2 copper-nickel-PGE projec…